Regenerative medicine developer Biostage scraps Nasdaq uplisting, offering

[ad_1] jittawit.21/iStock via Getty Images Regenerative medicine developer Biostage (OTC:BSTG) has scrapped plans for an uplisting and accompanying public offering. Biostage said in an SEC filing that it was withdrawing its S-1 application. The company had originally filed for the offering in June 2022. It later indicated in a November filing that it was looking … Read more